@forrestfield and to all other that are attending the WA Seminar,
It hasn't been confirmed whether Q&A will be allowed. If there is an opportunity to ask questions, please note the following suggestions to Patrick, Mark R, Mark F and Matt W. If these questions are covered off during the session, I will gladly reciprocate the favour at the Sydney event for any follow up questions or clarifications, you and the IAM community have.
I am not concerned with the wording of the question, but rather the key point or essence of the question itself. Also, if we get clear and direct answers, then great. But in the instance where the response is vague, general or coy-ish, please note their body language, words and standard non-verbal ques etc.
1. Let's start with the obvious one - Financials/Revenue and M1-M4 timeframes. Are they on track? Are they ahead, behind? Scale of revenue, margins? Costs and operational and development expenses? Capital raisings still not on the table in the short term?
2. More details of the Sentry HOA. Volumes expected to be given by Sentry to IAM? What issues they are likely to encounter? What does "preferred licensee in the non-aligned independent sector" exactly mean?
3. Pipeline - Any details on other clients to expect and when (e.g. size, Part of the big 4, timeframes)? What is their overall marketing and sales strategy. For example, are they still highly selective with their clients, are they turning to other distribution channels and client segments? Are all other clients onboarding likely to go through the same process as Sentry?
4. Risks - What are the major risks they see during the aggressive growth phase (i.e. now)? Is it macro-environment, competition, regulatory, keeping up with demand, skills/people/training
5. Operations and Technology - How are things progressing with Lily and Klip? When will the general market receive more information on the development and workings of these practice management tools? Are these the key differentiator for IAM or is it the outsourcing which is their main focus?
6. Investor Relations and PR - Can they set any expectations on how often they wish to keep the market and shareholders informed beyond the mandatory disclosure requirements?
I am sure you each have your own list of questions and versions, but I hope the above complement these.
If there is no formal Q&A session, I'm sure we'll hear about it and we will see "in the fullness of time".
Again, I will do my best to attend the Sydney event once announced and happy to collate and ask any questions not already covered in prior states.
#QANDA Over...
Bodhi_Trader
- Forums
- ASX - By Stock
- CF1
- Ann: Intiger to host Investor Seminar-IAM.AX
CF1
complii fintech solutions ltd
Add to My Watchlist
0.00%
!
2.4¢

Ann: Intiger to host Investor Seminar-IAM.AX, page-279
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
2.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $13.71M |
Open | High | Low | Value | Volume |
2.4¢ | 2.4¢ | 2.4¢ | $10.14K | 422.5K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 77411 | 2.4¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
2.7¢ | 29908 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 77411 | 0.024 |
3 | 783071 | 0.020 |
1 | 100000 | 0.016 |
3 | 912562 | 0.015 |
1 | 70000 | 0.014 |
Price($) | Vol. | No. |
---|---|---|
0.027 | 29908 | 1 |
0.028 | 506514 | 2 |
0.029 | 113723 | 1 |
0.030 | 500000 | 1 |
0.039 | 110820 | 1 |
Last trade - 11.55am 02/07/2025 (20 minute delay) ? |
Featured News
CF1 (ASX) Chart |
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Dr. Steven Gourlay, CEO
Dr. Steven Gourlay
CEO
Previous Video
Next Video
SPONSORED BY The Market Online